Quidel has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Lyra SARS-CoV-2 assay, a real-time reverse transcription polymerase chain reaction (RT-PCR) test for the novel coronavirus.
Quidel's Lyra line of products also includes PCR reagent kits. The Lyra SARS-CoV-2 assay is currently only available in the U.S., and it can be purchased through Quidel or Cardinal Health, the company said.
